

Via Electronic Filing System
Date of Deposit: April 14, 2006

Attorney Docket No.: 24852-501 CIP3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Bacopoulos et al. CONFIRMATION NUMBER: 6445
SERIAL NUMBER: 10/650,025 EXAMINER: PHYLLIS G. SPIVACK
FILING DATE: August 26, 2003 ART UNIT: 1614
FOR: **METHODS OF TREATING MESOTHELIOMA WITH
SUBEROYLANILIDE HYDROXAMIC ACID**

OFFICE OF PETITIONS
Mail Stop 313(c)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the enclosed Modified Form 1449/PTO in the above-identified patent application. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and publications are not required.

This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination (RCE) and a Petition to Withdraw from Issue After Payment of Issue Fee Under 37 C.R.R. § 1.313(c)(2). Accordingly, no fee is considered due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

Applicants: Bacopoulos, *et al.*
U.S.S.N.: 10/650,025

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24852-501 CIP3, Customer No. 35437.

Respectfully submitted,

Dated: April 14, 2006



Ivor R. Elrifi, Reg. No. 39,529
Caryn DeHoratius, Reg. No. 45,881
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Tel: (212) 935-3000
Fax: (212) 983-3115

Please type a plus sign (+) in this box



PTO/SB (12-97)

OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/650,025
	Filing Date	August 26, 2003
	First Named Inventor	Bacopoulos, <i>et al.</i>
	Group Art Unit / Conf. No.	1614 / 6445
	Examiner Name	Phyllis G. Spivack
	Attorney Docket Number	24852-501 CIP3

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A25	4,690,918	09/01/87	Beppu, et al.			
	A26	5,654,333	08/05/97	The United States of America as represented by the Department of Health and Human Services			
	A27	6,239,176	05/29/01	Beacon Laboratories, Inc. et al.			
	A28	6,262,116	07/17/01	Sloan-Kettering Institute for Cancer Research			
	A29	6,451,334	09/17/02	Perrine			
	A30	6,495,719	12/17/02	CircaGen Pharmaceutical			
	A31	2003/0114525	06/19/03	Kammer, et al.			
	A32	2004/0132643	07/08/04	Fojo, et al.			
	A33	2004/0167184	08/26/04	Wiech, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes	No
	B14	WO	98/39965	Beacon Laboratories, LLC	09/17/98	X	
	B15	WO	02/15921	The Government of the United States of America	02/28/02	X	
	B16	WO	02/055017	Wake Forest University	07/18/02	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C86	"Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA", October 30, 2002.
	C87	"Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias", July 1, 2003.
	C88	"Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development", September 20, 2002.
	C89	"Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO", June 2, 2003.
	C90	"Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium", November 21, 2002.
	C91	"Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial", October 13, 2003.
	C92	"Aton Pharma, Inc. Reports on Phase I Trial of SAHA", August 14, 2002.
	C93	Adhikari, D et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1998), Vol. 39, p 312, "Radiosensitization of Lymphoma Cell Lines by Sodium Butyrate".

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C94	Alexandrov, I et al., FEBS Letters, (1998), Vol. 434, pp 209-214, "Sodium Butyrate Suppresses Apoptosis in Human Burkitt Lymphomas and Murine Plasmacytomas Bearing c-myc Translocations".
	C95	Almenara, J et al., Leukemia (2002), Vol. 16, pp 1331-1343, "Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA)".
	C96	Amin HM et al., British Journal of Haematology (2001), Vol. 115, pp 287-297, "Histone Deacetylase Inhibitors Induce Caspase-Dependent Apoptosis and Downregulation of Daxx in Acute Promyelocytic Leukaemia with t(15;17)".
	C97	Aron, JL et al., Blood (2003), Vol. 102, No. 2, pp 652-658, "Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent With Activation of Caspase 8-mediated Apoptosis and Down-Regulation of c-FLIP Protein".
	C98	Benoit, NE et al., Immunopharmacology, (1996), Vol. 35, pp 129-139, "Increased inhibition of Proliferation of Human B Cell Lymphomas Following Ligation of CD40, and Either CD19, CD20, CD95 or Surface Immunoglobulin".
	C99	Bode, J et al., Journal of Interferon Research, (1982), Vol. 2, No. 2, pp 159-166, "Links Between Effects of Butyrate on Histone Hyperacetylation and Regulation of interferon Synthesis in Namalva and FS-4 Cell Lines".
	C100	Buckley, AR et al., Cell Growth & Differentiation (1996), Vol. 7, pp 1713-1721, "Alterations in pim-1 and c-myc Expression Associated with Sodium Butyrate-induced Growth Factor Dependency in Autonomously Rat Nb2 Lymphoma Cells".
	C101	Buckley, AR et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1997), Vol. 38, p 193, "Reversal of Apoptosis Resistance by Butyrate in rat Nb2 Lymphoma Cells".
	C102	Byrd, JC et al., Blood (1999), Vol. 94, No. 4, pp 1401-1408, "Depsipeptide (FR901228): A Novel Therapeutic Agent with Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells".
	C103	Carducci, MA et al., Clinical Cancer Research (2001), Vol. 7, No. 10, pp 3047-3055, "A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule".
	C104	Dear, AE et al., Biochimica et Biophysica Acta, (2000), Vol. 1492, pp 15-22, "The Novel Anti-Tumour Agent Oxamflatin Differentially Regulates Urokinase and Plasminogen Activator Inhibitor Type 2 Expression and Inhibits Urokinase-Mediated Proteolytic Activity".
	C105	Desai, D et al., Anticancer Research (2003), Vol. 23, pp 499-504, "Chemopreventive Efficacy of Suberoylanilide Hydroxamic Acid (SAHA) Against 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced Lung Tumorigenesis in Female A/J Mice".
	C106	Dhordain, P et al., Nucleic Acids Research, (1998), Vol. 26, No. 20, pp 4645-4651, "The LAZ3(BCL-6) Oncoprotein Recruits a SMRT/mSIN3A/Histone Deacetylase Containing Complex to Mediate Transcriptional Repression".
	C107	Edelman, MJ et al., Cancer Chemotherapy and Pharmacology (2003), Vol. 51, pp 439-444, "Clinical and Pharmacologic Study of Tributyrin: An Oral Butyrate Prodrug".
	C108	Feinman, R et al., Blood (2002), Vol. 100, No. 11, pp Abstract 3195, "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxyamic Acid, Induces Apoptosis of Multiple Myeloma Cells".
	C109	Fillpovich, I et al., Biochemical and Biophysical Research Communications, (1994), Vol. 198, pp 257-265, "Butyrate Induced Apoptosis in Lymphoid Cells Preceded by Transient Over-Expression of HSP70 mRNA".
	C110	Foss, FM et al., Blood, (1993), Vol. 82, No. 10, Suppl. 1, p 564A, "Biomodulatory Effects of Butyric Acid Derivatives on Leukemia and Lymphoma Cells".
	C111	Gelmetti, V et al., Molecular and Cellular Biology (1998), Vol. 18, No. 12, pp 7185-7191, "Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO".
	C112	Gerbitz, A, Oncogene, (1999), Vol. 18, pp 1745-1753, "Deregulation of the Proto-Oncogene c-myc Through t(8;22) Translocation in Burkitt's Lymphoma".
	C113	Gilbert, J et al., Clinical Cancer Research (2001), Vol. 7, No. 8, pp 2292-2300, "A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies".
	C114	Grisolano, JL et al., Proceedings of the National Academy of Sciences (2003), Vol. 100, No. 16, pp 9506-9511, "An Activated Receptor Tyrosine Kinase, TEL/PDGFbetaR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice".

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C115	Harris, NL et al., Blood (1994), Vol. 84, No. 5, pp 1361-1392, "A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group".
	C116	Jaboin, J et al., Cancer Research (2002), Vol. 62, No. 21, pp 6108-6115, "MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors".
	C117	Kurita-Ochiai, T et al., Infection and Immunity, (1998), Vol. 66, No. 6, pp 2587-2594, "Volatile Fatty Acid, Metabolic By-Product of Periodontopathic Bacteria, Induces Apoptosis in WEHI 231 and RAJI B Lymphoma Cells and Splenic B Cells".
	C118	Liu, Z et al., Journal of Cancer Research and Clinical Oncology, (1998), Vol. 124, pp 541-548, "Synergistic Effect of Epstein-Barr Virus and Tumor Promoters on Induction of Lymphoma and Carcinoma in Nude Mice".
	C119	Madisen, L et al., Molecular and Cellular Biology, (1998), Vol. 18, No. 11, pp 6281-6292, "The Immunoglobulin Heavy Chain Locus Control Region Increases Histone Acetylation along Linked c-myc Genes".
	C120	Niitsu, N et al., Molecular Pharmacology, (2000), Vol. 58, pp 27-36, "Anticancer Derivative of Butyric Acid (Pivalyloxymethyl Butyrate) Specifically Potentiates the Cytotoxicity of Doxorubicin and Daunorubicin Through the Suppression of Microsomal Glycosidic Activity".
	C121	Orr, D et al., 2000 ASCO Annual Meeting, Abstract No. 763, "Phase I Pharmacokinetic (PK) Study of CI-994 in Combination with Gemcitabine (GEM) in Patients with Advanced Solid Tumors".
	C122	Polack, A et al., The EMBO Journal, (1993), Vol. 12, No. 10, pp 3913-3920, "Regulatory Elements in the Immunoglobulin Kappa Locus Induce c-myc Activation and the Promoter Shift in Burkitt's Lymphoma Cells".
	C123	Rezuke, WN et al., Clinical Chemistry (1997), Vol. 43, No. 10, pp 1814-1823, "Molecular Diagnosis of B- and T-cell Lymphomas: Fundamental Principles and Clinical Applications".
	C124	Rottlieb, C et al., International Journal of Cancer, (1995), Vol. 62, pp 697-702, "Among 17 Inducers of Differentiation Only Sodium Butyrate Causes a Permanent Down-Regulation of c-myc in Burkitt's Lymphoma".
	C125	Rottlieb, C et al., International Journal of Cancer, (1996), Vol. 67, pp 724-729, "Structure-Activity Relationship of 17 Structural Analogues of N-Butyric Acid Upon c-myc Expression".
	C126	Rubio, MA et al., Blood, (1995), Vol. 86, No. 10, pp 3715-3724, "Granulocyte-Macrophage Colony-Stimulating Factor, Phorbol Ester, and Sodium Butyrate Induce the CD11c Integrin Gene Promoter Activity During Myeloid Cell Differentiation".
	C127	Schrump, DS et al., Clinical Lung Cancer (2002), Vol. 4, No. 3, pp 186-192, "Phase I Study of Sequential Deoxyazacytidine/depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura".
	C128	Vrana JA et al., Oncogene (1999), Vol. 18, pp 7016-7025, "Induction of Apoptosis in U937 Human Leukemia Cells by Suberoylanilide Hydroxamic Acid (SAHA) Proceeds Through Pathways That are Regulated by Bcl-2/Bcl-X _L , c-Jun, and p21 ^{CIP1} , but independent of p53".
	C129	Watanabe, M et al., Cancer Research (1990), Vol. 50, pp 3245-3248, "Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma".
	C130	Yu, C et al., Cancer Research (2001), Vol. 63, pp 2118-2126, "Histone Deacetylase Inhibitors Promote STI571-Mediated Apoptosis in STI571-Sensitive and -Resistant Bcr/Abl ⁺ Human Myeloid Leukemia Cells".
	C131	Zhang, M et al., Cell Stress & Chaperones, (1998), Vol 3, No. 1, pp 57-66, "Heat-Induced Proteolysis of HSF Causes Premature Deactivation of the Heat Shock Response in Nb2 Lymphoma Cells".

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered..Include copy of this form with next communication to Applicants...